Mar 13 |
Liver drug developers outperform as U.S. awaits first NASH drug
|
Mar 9 |
Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.
|
Mar 6 |
Citi starts Madrigal at buy, cites upcoming FDA decision on NASH drug
|
Mar 5 |
Madrigal gains as NASH therapy undergoes EU review
|
Mar 5 |
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis
|
Mar 5 |
1 Wall Street Analyst Thinks Madrigal Pharmaceuticals Stock Is Going to $347. Is It a Buy Around $247?
|
Feb 28 |
Madrigal Pharmaceuticals: Q4 Earnings Insights
|
Feb 28 |
Madrigal Pharmaceuticals names Mardi Dier as CFO
|
Feb 28 |
Madrigal Pharmaceuticals GAAP EPS of -$5.68 misses by $0.42
|
Feb 28 |
Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer
|